Euroscreen is a private Belgian, preclinical-stage, Drug Discovery and Development Company providing first-in-class small molecule drug candidates to address several therapeutic areas including inflammation, metabolism and sex hormone modulation. Euroscreen has a track-record on multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR) due to its recognized know-how and expertise with these targets; having achieved in vivo proof of concept and efficacy in multiple preclinical programs.
Euroscreen is moving forward to advance a program of its own into clinical trials, and also actively seeks collaborations to advance other pharmaceutical candidates, in addition to its ongoing research and licensing partnerships with several pharmaceutical companies as Boehringer-Ingelheim, Cephalon, Grunenthal, HGS, Ortho-McNeil-Janssen Pharmaceuticals, Inc, Monogram Biosciences, Novartis and Pfizer.
Euroscreen also offers a broad patent portfolio for targets and screening tools to out-license to companies developing therapeutic drugs acting through targets as CCR5, Chemerin Receptor, GPR43 antagonists, GPR7/8, ORL1-R, FPRL2, P2Y4, P2Y11 and P2Y13.
In addition to pursuing its drug discovery pipeline, Euroscreen also provides GPCR custom testing services around the world which include HTS-screening, lead optimization support, candidate profiling and target deorphanization/characterization through the services of its Euroscreen FAST Business Unit.